Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

100 years of Lewy pathology

Abstract

In 1817, James Parkinson described the symptoms of the shaking palsy, a disease that was subsequently defined in greater detail, and named after Parkinson, by Jean-Martin Charcot. Parkinson expected that the publication of his monograph would lead to a rapid elucidation of the anatomical substrate of the shaking palsy; in the event, this process took almost a century. In 1912, Fritz Heinrich Lewy identified the protein aggregates that define Parkinson disease (PD) in some brain regions outside the substantia nigra. In 1919, Konstantin Nikolaevich Tretiakoff found similar aggregates in the substantia nigra and named them after Lewy. In the 1990s, α-synuclein was identified as the main constituent of the Lewy pathology, and its aggregation was shown to be central to PD, dementia with Lewy bodies, and multiple system atrophy. In 2003, a staging scheme for idiopathic PD was introduced, according to which α-synuclein pathology originates in the dorsal motor nucleus of the vagal nerve and progresses from there to other brain regions, including the substantia nigra. In this article, we review the relevance of Lewy's discovery 100 years ago for the current understanding of PD and related disorders.

Key Points

  • 100 years ago, Fritz Heinrich Lewy used light microscopy to describe the nerve cell inclusions that are characteristic of Parkinson disease (PD)

  • The Lewy pathology consists of the protein α-synuclein in an insoluble form

  • Missense and gene dosage mutations in SNCA, the α-synuclein gene, cause inherited cases of PD and dementia with Lewy bodies

  • In PD, α-synuclein pathology is widespread in the CNS and PNS

  • α-Synuclein pathology originates in a small number of nerve cells, from which it spreads in a prion-like fashion

  • Clinically, the development of the pathological changes of PD is reflected by the presence of nonmotor and motor symptoms

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: 100 years of Lewy pathology: timeline of discoveries.
Figure 2: Members of Alois Alzheimer's research group at the Royal Psychiatric Clinic of the University of Munich, Germany in 1910.
Figure 3: Abnormal nerve cell bodies and processes in the dorsal motor nucleus of the vagal nerve in Parkinson disease.
Figure 4: Human α-synuclein and its disease-causing mutations.
Figure 5: Synuclein-immunoreactive Lewy pathology in the Parkinson disease brain.
Figure 6: Synuclein-immunoreactive Lewy pathology in the PD spinal cord, coeliac ganglion and gastrointestinal tract.
Figure 7: Six stages of PD pathology.
Figure 8: Stages 3–6 of Parkinson disease pathology.

Similar content being viewed by others

References

  1. Lewy, F. Paralysis agitans. I. Pathologische Anatomie. In Handbuch der Neurologie Vol. 3 (eds Lewandowsky, M. & Abelsdorff, G.) 920–933 (Springer-Verlag, Berlin, 1912).

    Google Scholar 

  2. Tretiakoff, C. Contribution à l'étude de l'anatomie pathologique du locus niger de Soemmering avec quelques déductions relatives à la pathogénie des troubles du tonus musculaire et de la maladie de Parkinson. Thesis, University of Paris (1919).

    Google Scholar 

  3. Braak, H. et al. Amygdala pathology in Parkinson's disease. Acta Neuropathol. 88, 493–500 (1994).

    CAS  PubMed  Google Scholar 

  4. Polymeropoulos, M. H. et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045–2047 (1997).

    CAS  PubMed  Google Scholar 

  5. Spillantini, M. G. et al. α-Synuclein in Lewy bodies. Nature 388, 839–840 (1997).

    CAS  PubMed  Google Scholar 

  6. Satake, W. et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41, 1303–1307 (2009).

    CAS  PubMed  Google Scholar 

  7. Simón-Sánchez, J. et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41, 1308–1311 (2009).

    PubMed  PubMed Central  Google Scholar 

  8. Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197–211 (2003).

    PubMed  Google Scholar 

  9. Holdorff, B. Friedrich Heinrich Lewy (1885–1950) and his work. J. Hist. Neurosci. 11, 19–28 (2002).

    PubMed  Google Scholar 

  10. Rodrigues e Silva, A. M. et al. Who was the man who discovered the “Lewy bodies”? Mov. Disord. 25, 1765–1773 (2010).

    PubMed  Google Scholar 

  11. Sweeney, P. J., Lloyd, M. F. & Daroff, R. B. What's in a name? Dr. Lewey and the Lewy body. Neurology 49, 629–630 (1997).

    CAS  PubMed  Google Scholar 

  12. Lewy, F. H. Zur pathologischen Anatomie der Paralysis agitans [German]. Dtsch. Z. f. Nervenheilk. 50, 50–55 (1913).

    Google Scholar 

  13. Lafora, G. R. & Glueck, B. Beitrag zur Histopathologie der myoklonischen Epilepsie [German]. Z. ges. Neurol. Psychiat. 6, 1–14 (1911).

    Google Scholar 

  14. Blocq, P. & Marinesco, G. Sur un cas de tremblement parkinsonien hémiplégique symptomatique d'une tumeur du pédoncule cérébral [French]. C. R. Soc. Biol. 5, 105–111 (1893).

    Google Scholar 

  15. Lewy, F. H. Die Lehre vom Tonus und der Bewegung (Springer-Verlag, Berlin, 1923).

    Google Scholar 

  16. Hassler, R. Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus [German]. J. Psychol. Neurol. 48, 387–455 (1938).

    Google Scholar 

  17. Lewy, F. H. Die Entstehung der Einschlusskörper und ihre Bedeutung für die systematische Einordnung der sogenannten Viruskrankheiten [German]. Dtsch. Z. f. Nervenheilk. 124, 93–100 (1932).

    Google Scholar 

  18. Goedert M., Clavaguera, F. & Tolnay, M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci. 33, 317–325 (2010).

    CAS  PubMed  Google Scholar 

  19. Lewy, F. H. Historical introduction: the diseases of the basal ganglia. Res. Publ. Ass. Nerv. Ment. Dis. 21, 1–20 (1942).

    Google Scholar 

  20. de Lau, L. M. & Breteler, M. M. Epidemiology of Parkinson's disease. Lancet Neurol. 5, 525–535 (2006).

    PubMed  Google Scholar 

  21. Reid, W. G., Hely, M. A., Morris, J. G., Loy, C. & Halliday, G. M. Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). J. Neurol. Neurosurg. Psychiatry 82, 1033–1037 (2011).

    CAS  PubMed  Google Scholar 

  22. Braak, H. & Del Tredici, K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv. Anat. Embryol. Cell Biol. 201, 1–119 (2009).

    PubMed  Google Scholar 

  23. Krüger, R. et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18, 106–108 (1998).

    PubMed  Google Scholar 

  24. Zarranz, J. J. et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164–173 (2004).

    CAS  PubMed  Google Scholar 

  25. Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492–501 (2001).

    CAS  PubMed  Google Scholar 

  26. Singleton, A. B. et al. α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841 (2003).

    CAS  PubMed  Google Scholar 

  27. Chartier-Harlin, M. C. et al. α-Synuclein locus duplication in a case of familial Parkinson's disease. Lancet 364, 1167–1169 (2004).

    CAS  PubMed  Google Scholar 

  28. Ibanez, P. et al. Causal relation between α-synuclein gene duplication and familial Parkinson's disease. Lancet 364, 1169–1171 (2004).

    CAS  PubMed  Google Scholar 

  29. Krüger, R. et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined α-synuclein/apolipoprotein E genotype. Ann. Neurol. 45, 611–617 (1999).

    PubMed  Google Scholar 

  30. Poulopoulos, M., Levy, O. A. & Alcalay, R. N. The neuropathology of genetic Parkinson's disease. Mov. Disord. 27, 831–842 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Kanazawa, T. et al. Pale neurites, premature α-synuclein aggregates with centripetal extension from axon collaterals. Brain Pathol. 22, 67–78 (2012).

    PubMed  Google Scholar 

  32. Cremades, N. et al. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 149, 1048–1059 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Dickson, D. W. et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol. 115, 437–444 (2008).

    PubMed  Google Scholar 

  34. Josephs, K. A., Parisi, J. E. & Dickson, D. W. Alpha-synuclein studies are negative in post-encephalitic parkinsonism of von Economo. Neurology 59, 645–646 (2002).

    PubMed  Google Scholar 

  35. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469–6473 (1998).

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Serpell, L. C., Berriman, J., Jakes, R., Goedert, M. & Crowther, R. A. Fibre diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation. Proc. Natl Acad. Sci. USA 97, 4897–4902 (2000).

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Vilar, M. et al. The fold of α-synuclein fibrils. Proc. Natl Acad. Sci. USA 105, 8637–8642 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Fujiwara, H. et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160–164 (2002).

    CAS  PubMed  Google Scholar 

  39. Anderson, J. P. et al. Phosphorylation of Ser-129 is the dominant modification of α-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739–29752 (2006).

    CAS  PubMed  Google Scholar 

  40. Kuusisto, E., Parkkinen, L. & Alazuloff, I. Morphogenesis of Lewy bodies: dissimilar incorporation of α-synuclein, ubiquitin, and p62. J. Neuropathol. Exp. Neurol. 62, 1241–1253 (2003).

    CAS  PubMed  Google Scholar 

  41. McKeith, I. et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65, 1863–1872 (2005).

    CAS  PubMed  Google Scholar 

  42. Kosaka, K. & Manabe, Y. The first autopsied case of diffuse Lewy body disease (DLBD); re-examination by recent immunostaining methods. Neuropathology 30, 458–462 (2010).

    PubMed  Google Scholar 

  43. Kotzbauer, P. T., Trojanowski, J. Q. & Lee, V. M. Lewy body pathology in Alzheimer's disease. J. Mol. Neurosci. 17, 225–232 (2001).

    CAS  PubMed  Google Scholar 

  44. Lee, H. G., Zhu, X., Takeda, A., Perry, G. & Smith, M. A. Emerging evidence for the neuroprotective role of α-synuclein. Exp. Neurol. 200, 1–7 (2006).

    CAS  PubMed  Google Scholar 

  45. Saha, A. R. et al. Parkinson's disease α-synuclein mutations exhibit defective axonal transport in cultured neurons. J. Cell Sci. 117, 1017–1024 (2004).

    CAS  PubMed  Google Scholar 

  46. Beach, T. G. et al. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol. 115, 445–451 (2008).

    CAS  PubMed  Google Scholar 

  47. Dugger, B. N. & Dickson, D. W. Cell type-specific sequestration of choline acetyltransferase and tyrosine hydroxylase within Lewy bodies. Acta Neuropathol. 120, 633–639 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Del Tredici, K. & Braak, H. Spinal cord lesions in sporadic Parkinson's disease. Acta Neuropathol. 124, 643–664 (2012).

    CAS  PubMed  Google Scholar 

  49. Braak, H., Sastre, M., Bohl, J. R., de Vos, R. A. & Del Tredici, K. Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol. 113, 421–429 (2007).

    PubMed  Google Scholar 

  50. Wakabayashi, K., Takahashi, H., Ohama, E. & Ikuta, F. Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol. 79, 581–583 (1990).

    CAS  PubMed  Google Scholar 

  51. Pouclet, H. et al. A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson's disease. Neurobiol. Dis. 45, 305–309 (2012).

    PubMed  Google Scholar 

  52. Wakabayashi, K. & Takahashi, H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur. Neurol. 38 (Suppl. 2), 2–7 (1997).

    PubMed  Google Scholar 

  53. Fumimura, Y. et al. Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in Lewy body disease. J. Neuropathol. Exp. Neurol. 66, 354–362 (2007).

    PubMed  Google Scholar 

  54. Del Tredici, K., Hawkes, C. H., Ghebremedhin, E. & Braak, H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol. 119, 703–713 (2010).

    PubMed  Google Scholar 

  55. Iwanaga, K. et al. Lewy body-type degeneration in cardiac plexus in Parkinson's disease and incidental Lewy body diseases. Neurology 52, 1269–1271 (1999).

    CAS  PubMed  Google Scholar 

  56. Orimo, S. et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol. 109, 583–588 (2005).

    PubMed  Google Scholar 

  57. Ghebremedhin, E., Del Tredici, K., Langston, J. W. & Braak, H. Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson's disease: an anatomical study. Acta Neuropathol. 118, 777–784 (2009).

    CAS  PubMed  Google Scholar 

  58. Jellinger, K. A. Pathology of Parkinson's disease. Changes other than in the nigrostriatal pathway. Mol. Chem. Neuropathol. 14, 153–197 (1991).

    CAS  PubMed  Google Scholar 

  59. Lang, A. E. & Obeso, J. A. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol. 3, 309–316 (2004).

    PubMed  Google Scholar 

  60. Langston, J. W. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann. Neurol. 59, 591–596 (2006).

    PubMed  Google Scholar 

  61. Dickson, D. W. et al. Neuropathology of non-motor features of Parkinson's disease. Parkinsonism Relat. Disord. 15 (Suppl. 3), S1–S5 (2009).

    PubMed  Google Scholar 

  62. Lim, S. Y., Fox, S. H. & Lang, A. E. Overview of the extranigral aspects of Parkinson disease. Arch. Neurol. 66, 167–172 (2009).

    PubMed  Google Scholar 

  63. Bloch, A., Probst, A., Bissig, H., Adams, H. & Tolnay, M. α-Synuclein pathology of the spinal and peripheral autonomic nmervous system in neurologically unimpaired elderly subjects. Neuropathol. Appl. Neurobiol. 12, 284–295 (2006).

    Google Scholar 

  64. Dickson, D. W., Uchikado, H., Fujishiro, H. & Tsuboi, Y. Evidence in favour of Braak staging of Parkinson's disease. Mov. Disord. 25 (Suppl. 1), S78–S82 (2010).

    PubMed  Google Scholar 

  65. Halliday, G., McCann, H. & Shepherd, C. Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease? Expert Rev. Neurother. 12, 673–686 (2012).

    CAS  PubMed  Google Scholar 

  66. Braak, H. et al. Pathology associated with sporadic Parkinson's disease—where does it end? J. Neural Transm. 70, 89–97 (2006).

    Google Scholar 

  67. Uchikado, H., Lin, W. L., De Lucia, M. W. & Dickson, D. W. Alzheimer disease with amygdala Lewy bodies: a distinct form of α-synucleinopathy. J. Neuropathol. Exp. Neurol. 65, 685–697 (2006).

    CAS  PubMed  Google Scholar 

  68. Saito, Y. et al. Lewy body-related α-synucleinopathy in aging. J. Neuropathol. Exp. Neurol. 63, 742–749 (2004).

    PubMed  Google Scholar 

  69. Beach, T. G. et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 117, 613–634 (2009).

    PubMed  PubMed Central  Google Scholar 

  70. Dickson, D. W. et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol. 8, 1150–1157 (2009).

    CAS  PubMed  Google Scholar 

  71. Braak, H., de Vos, R. A., Bohl, J. & Del Tredici, K. Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci. Lett. 396, 67–72 (2006).

    CAS  PubMed  Google Scholar 

  72. Del Tredici, K. & Braak, H. Lewy pathology and neurodegeneration in premotor Parkinson's disease. Mov. Disord. 27, 597–607 (2012).

    PubMed  Google Scholar 

  73. Annerino, D. M. et al. Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol. 124, 665–680 (2012).

    PubMed  PubMed Central  Google Scholar 

  74. Shannon, K. M., Keshavarzian, A., Dodiya, H. B., Jakate, S. & Kordower, J. H. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov. Disord. 27, 716–719 (2012).

    PubMed  Google Scholar 

  75. Klos, K. J. et al. α-Synuclein pathology in the spinal cord of neurologically asymptomatic aged individuals. Neurology 66, 1100–1102 (2006).

    CAS  PubMed  Google Scholar 

  76. Schapira, A. H. & Tolosa, E. Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat. Rev. Neurol. 6, 309–317 (2010).

    CAS  PubMed  Google Scholar 

  77. Li, J. Y. et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14, 501–503 (2008).

    CAS  PubMed  Google Scholar 

  78. Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B. & Olanow, C. W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14, 504–506 (2008).

    CAS  PubMed  Google Scholar 

  79. Ahn, T. B., Langston, W. J., Aachi, V. R. & Dickson, D. W. Relationship of neighbouring tissue and gliosis to α-synuclein pathology in a fetal transplant for Parkinson's disease. Am. J. Neurodegener. Dis. 1, 49–59 (2012).

    PubMed  PubMed Central  Google Scholar 

  80. Li, J. Y. et al. Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov. Disord. 25, 1091–1096 (2010).

    PubMed  Google Scholar 

  81. Greffard, S. et al. A stable proportion of Lewy body-bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death. Neurobiol. Aging 31, 99–103 (2010).

    CAS  PubMed  Google Scholar 

  82. Prusiner, S. B. A unifying role for prions in neurodegenerative diseases. Science 336, 1511–1513 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  83. Parkkinen, L. et al. Disentangling the relationship between Lewy bodies and nigral neuronal loss in Parkinson's disease. J. Parkinsons Dis. 1, 277–286 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Hawkes, C. J., Del Tredici, K. & Braak, H. A timeline for Parkinson's disease. Parkinsonism Relat. Disord. 16, 79–84 (2010).

    PubMed  Google Scholar 

  85. Neudorfer, O. et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. Q. J. Med. 89, 691–694 (1996).

    CAS  Google Scholar 

  86. Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361, 1651–1661 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Rosenbloom, B. et al. The incidence of parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry. Blood Cells Mol. Dis. 46, 95–102 (2011).

    PubMed  Google Scholar 

  88. Goker-Alpan, O., Stubblefield, B. K., Giasson, B. I. & Sidransky E. Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders. Acta Neuropathol. 120, 641–649 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  89. Westbroek, W., Gustafson, A. M. & Sidransky, E. Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol. Med. 17, 485–493 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  90. Paisán-Ruíz, C. et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595–600 (2004).

    PubMed  Google Scholar 

  91. Zimprich, A. et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601–607 (2004).

    CAS  PubMed  Google Scholar 

  92. Ross, O. A. et al. Lrrk2 and Lewy body disease. Ann. Neurol. 59, 388–393 (2006).

    CAS  PubMed  Google Scholar 

  93. Kitada, T. et al. Mutations in the Parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605–608 (1998).

    CAS  PubMed  Google Scholar 

  94. Valente, E. M. et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158–1160 (2004).

    CAS  PubMed  Google Scholar 

  95. Park, J. et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441, 1157–1161 (2006).

    CAS  PubMed  Google Scholar 

  96. Clark, I. E. et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441, 1162–1166 (2006).

    CAS  PubMed  Google Scholar 

  97. Kondapalli, C. et al. PINK1 is activated by mitochondrial membrane depolarization and stimulates Parkin E3 ligase activity by phosphorylating serine 65. Open Biol. 2, 120080 (2012).

    PubMed  PubMed Central  Google Scholar 

  98. Youle, R. J. & Narendra, D. P. Mechanisms of mitophagy. Nat. Rev. Mol. Cell. Biol. 12, 9–14 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  99. Bonifati, V. et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256–259 (2003).

    CAS  PubMed  Google Scholar 

  100. Canet-Avilés, R. M. et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl Acad. Sci. USA 101, 9103–9108 (2004).

    PubMed  PubMed Central  Google Scholar 

  101. Zarow, C., Lyness, S. A., Mortimer, J. A. & Chui, H. C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60, 337–341 (2003).

    PubMed  Google Scholar 

  102. Samaranch, L. et al. PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 133, 1128–1142 (2010).

    PubMed  Google Scholar 

  103. Papp, M. I., Kahn, J. E. & Lantos, P. L. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy. J. Neurol. Sci. 94, 79–100 (1989).

    CAS  PubMed  Google Scholar 

  104. Wakabayashi, K., Yoshimoto, M., Tsuji, S. & Takahashi, H. α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci. Lett. 249, 180–182 (1998).

    CAS  PubMed  Google Scholar 

  105. Spillantini, M. G. et al. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205–208 (1998).

    CAS  PubMed  Google Scholar 

  106. Tu, P. H. et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein. Ann. Neurol. 44, 415–422 (1998).

    CAS  PubMed  Google Scholar 

  107. Scholz, S. W. et al. SNCA variants are associated with increased risk for multiple system atrophy. Ann. Neurol. 65, 610–614 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  108. Al-Chalabi, A. et al. Genetic variants of the α-synuclein gene SNCA are associated with multiple system atrophy. PLoS ONE 22, e7114 (2009).

    Google Scholar 

  109. Abeliovich A. et al. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239–252 (2000).

    CAS  PubMed  Google Scholar 

  110. Specht, C. G. & Schoepfer, R. Deletion of the α-synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC Neurosci. 2, 11 (2001).

    CAS  PubMed  PubMed Central  Google Scholar 

  111. Greten-Harrison, B. et al. αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc. Natl Acad. Sci. USA 107, 19573–19578 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  112. McCormack, A. L. et al. α-Synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS ONE 5, e12122 (2010).

    PubMed  PubMed Central  Google Scholar 

  113. Lim, V. et al. α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J. Neurosci. 31, 10076–10087 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  114. Masliah, E. et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265–1269 (2000).

    CAS  PubMed  Google Scholar 

  115. Giasson, B. I. et al. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 34, 521–533 (2002).

    CAS  PubMed  Google Scholar 

  116. Emmer, K. L., Waxman, E. A., Covey, J. P. & Giasson, B. I. E46K human α-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. J. Biol. Chem. 286, 35104–35118 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  117. Lee, K. W. et al. Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model. J. Neurosci. 31, 6963–6971 (2012).

    Google Scholar 

  118. Tofaris, G. K. et al. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human α-synuclein(1–120): implications for Lewy body disorders. J. Neurosci. 26, 3942–3950 (2006).

    CAS  PubMed  PubMed Central  Google Scholar 

  119. Garcia-Reitböck, P. et al. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain 133, 2032–2044 (2010).

    PubMed  PubMed Central  Google Scholar 

  120. Betarbet, R. et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301–1306 (2000).

    CAS  PubMed  Google Scholar 

  121. Pan-Montojo, F. et al. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS ONE 5, e8762 (2010).

    PubMed  PubMed Central  Google Scholar 

  122. Kirik, D. et al. Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780–2791 (2002).

    CAS  PubMed  PubMed Central  Google Scholar 

  123. Lo Bianco, C., Ridet, J. L., Schneider, B. L., Deglon, N. & Aebischer, P. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl Acad. Sci. USA 99, 10813–10818 (2002).

    CAS  PubMed  PubMed Central  Google Scholar 

  124. Taschenberger, G. et al. Aggregation of α-synuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol. 123, 671–683 (2012).

    CAS  PubMed  Google Scholar 

  125. Burré, J., Sharma, M. & Südhof, T. C. Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities. J. Neurosci. 32, 15227–15242 (2012).

    PubMed  PubMed Central  Google Scholar 

  126. Feany, M. B. & Bender, W. W. A Drosophila model of Parkinson's disease. Nature 404, 394–398 (2000).

    CAS  PubMed  Google Scholar 

  127. Auluck, P. K., Chan, H. Y., Trojanowski, J. Q., Lee, V. M. & Bonini, N. M. Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295, 865–868 (2002).

    CAS  PubMed  Google Scholar 

  128. Periquet, M., Fulga, T., Myllykangas, L., Schlossmacher, M. G. & Feany, M. B. Aggregated α-synuclein mediates dopaminergic neurotoxicity in vivo. J. Neurosci. 27, 3338–3346 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  129. Lakso, M. et al. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human α-synuclein. J. Neurochem. 86, 165–172 (2003).

    CAS  PubMed  Google Scholar 

  130. Kuwahara, T. et al. A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in α-synuclein transgenic C. elegans. Hum. Mol. Genet. 17, 2997–3009 (2007).

    Google Scholar 

  131. Masuda, M. et al. Small molecule inhibitors of α-synuclein filament assembly. Biochemistry 45, 6085–6094 (2006).

    CAS  PubMed  Google Scholar 

  132. Volpicelli-Daley, L. A. et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57–71 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  133. Desplats, P. et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. Proc. Natl Acad. Sci. USA 106, 13010–13015 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  134. Hansen, C. et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 121, 715–725 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  135. Kordower, J. H. et al. Transfer of host-derived α-synuclein to grafted dopaminergic neurons in rat. Neurobiol. Dis. 43, 552–557 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  136. Mougenot, A. L. et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging 33, 2225–2228 (2012).

    CAS  PubMed  Google Scholar 

  137. Luk, K. C. et al. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J. Exp. Med. 209, 975–986 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  138. Masliah, E. et al. Effects of α-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46, 857–868 (2005).

    CAS  PubMed  Google Scholar 

  139. Masliah, E. et al. Passive immunization reduces behavioural and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE 6, e19338 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  140. Devine, M. J. et al. Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat. Commun. 2, 440 (2011).

    PubMed  Google Scholar 

  141. Soldner, F. et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146, 318–331 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  142. Duffy, P. E. & Tennyson, V. M. Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus coeruleus in Parkinson's disease. J. Neuropathol. Exp. Neurol. 24, 398–414 (1965).

    Google Scholar 

  143. Parkinson, J. An Essay on the Shaking Palsy (Sherwood, Nealy and Jones, London, 1817).

    Google Scholar 

  144. Charcot, J. M. Leçons sur les Maladies du Système Nerveux Vol. 1 (Delahaye et Cie, Paris, 1875).

    Google Scholar 

  145. Von Economo, C. Die Encephalitis lethargica [German]. Wien. klin. Wochenschr. 30, 581–585 (1917).

    Google Scholar 

  146. Vogt, C. & Vogt, O. Zur Lehre der Erkrankung des striären Systems [German]. J. Psychol. Neurol. 26, 43–57 (1920).

    Google Scholar 

  147. Bradbury, S. & Eggleston, C. Postural hypotension: a report of three cases. Am. Heart J. 1, 75–86 (1925).

    Google Scholar 

  148. Ehringer, H. & Hornykiewicz, O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems [German]. Klin. Wochenschr. 38, 1236–1239 (1960).

    CAS  PubMed  Google Scholar 

  149. Birkmayer, W. & Hornykiewicz, O. Der L-Dioxyphenylalanineffekt bei der Parkinson-Akinese [German]. Wien. klin. Wochenschr. 73, 787–788 (1961).

    CAS  PubMed  Google Scholar 

  150. Cotzias, G. C., Van Woert, M. H. & Schiffer, L. M. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. 276, 374–379 (1967).

    CAS  PubMed  Google Scholar 

  151. Hoehn, M. M. & Yahr, M. D. Parkinsonism: onset, progression and mortality. Neurology 17, 427–442 (1967).

    CAS  PubMed  Google Scholar 

  152. Calne, D. B., Stern, G. M., Laurence, D. R., Sharkey, J. & Armitage, P. L-DOPA in postencephalitic parkinsonism. Lancet 1, 744–747 (1969).

    CAS  PubMed  Google Scholar 

  153. Sacks, O. Awakenings (Duckworth, London, 1973).

    Google Scholar 

  154. Ansari, K. A. & Johnson, A. J. Olfactory function in Parkinson's disease. J. Chronic Dis. 28, 493–497 (1975).

    CAS  PubMed  Google Scholar 

  155. Kosaka, K., Oyanagi, S., Matsushita, M. & Hori, A. Presenile dementia with Alzheimer-, Pick- and Lewy-body changes. Acta Neuropathol. 36, 221–233 (1976).

    CAS  PubMed  Google Scholar 

  156. Langston, J. W., Ballard, P., Tetrud, J. & Irwin, I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979–980 (1983).

    CAS  PubMed  Google Scholar 

  157. Qualman, S., Haupt, H. M., Yang, P. & Hamilton, S. D. Esophageal Lewy bodies associated with ganglion cell loss in achalasia: similarity to Parkinson's disease. Gastroenterology 87, 848–856 (1984).

    CAS  PubMed  Google Scholar 

  158. Schenck, C. H., Bundle, S. R., Ettinger. M. G. & Mahowald, M. W. Chronic behavioural disorders of human REM sleep: a new category of parasomnia. Sleep 9, 293–308 (1986).

    CAS  PubMed  Google Scholar 

  159. Benabid, A. L., Pollak, P., Louveau, A., Henry, S. & de Rougemont, J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl. Neurophysiol. 50, 344–346 (1987).

    CAS  PubMed  Google Scholar 

  160. McKeith, I. G. et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB). Neurology 47, 1113–1124 (1996).

    CAS  PubMed  Google Scholar 

  161. Saiki, M. et al. Association of the human leucocyte antigen region with susceptibility to Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 81, 890–891 (2010).

    PubMed  Google Scholar 

  162. Braak, H. et al. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov. Disord. 21, 2042–2051 (2006).

    PubMed  Google Scholar 

Download references

Acknowledgements

We thank Mrs Nathalie Cornée for tracking down references from times past. This article was supported in part by the UK Medical Research Council (U105184291), Parkinson's UK and the Deutsche Forschungsgemeinschaft (grant TR 1000/1-1).

Author information

Authors and Affiliations

Authors

Contributions

All authors contributed to researching data for the article, discussions of the content, writing the article, and review and/or editing of the manuscript before submission.

Corresponding author

Correspondence to Michel Goedert.

Ethics declarations

Competing interests

M. Goedert has received research support from Eli Lilly, and has acted as a consultant for GlaxoSmithKline and Hoffmann-La Roche. The other authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goedert, M., Spillantini, M., Del Tredici, K. et al. 100 years of Lewy pathology. Nat Rev Neurol 9, 13–24 (2013). https://doi.org/10.1038/nrneurol.2012.242

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2012.242

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing